J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA's Gottlieb

09 Jan 2019

• By Mandy Jackson, Jessica Merrill, Emily Hayes, and Sue Sutter

Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: Biogen may be looking for gene therapy partner, Lilly CEO says Loxo is just the start, GSK plays up its BCMA, Amgen vows to put money into deals, Biohaven readies oral CGRP inhibitor to compete, and Roche talks value-based payments.

Classic view of historic traditional Cable Cars riding on famous California Street in morning light at sunrise with retro vintage style cross processing filter effect, San Francisco, California, USA - Image

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven, Lilly And FDA's Gottlieb

More from Strategy

More from Business